ASCO is supported by its affiliate organization, the Conquer Cancer Foundation, which funds ground-breaking research and programs that make a tangible difference in the lives of people with cancer. This annual meeting is one of the largest oncology conferences there is and will bring together more than 32,000 oncology professionals from around the world to discuss state-of-the-art treatment modalities, new therapies, and ongoing controversies in the field.
We hope to see you there and set up a meeting with one of our oncology scientific leaders to discuss how we can further streamline your clinical trial!
Glenn Kerkhof is Executive Chairman of George Clinical. Glenn has over 27 years’ experience in the contract research or drug development industry and joined George Clinical from Chiltern, where he was Chief Executive Officer. Before Chiltern, Glenn served as Vice President, Clinical Services for Charles River Laboratories, and as Vice President, Clinical Europe for Inveresk Research. Also, he is a non-executive director of Immunoglobal Pty. Ltd and his previous directorships include Cell Care Pty. Ltd. Glenn, based in Melbourne, works closely with the executive team to formulate and execute George Clinical’s global strategy.
As Chief Business Office for George Clinical, Sean Hart leads the U.S. and Asia-Pacific business development teams and directs global marketing and public relations efforts for George Clinical. Prior to joining George Clinical, Sean was the Executive Vice President and Managing Director of Vector Oncology overseeing the Global Pharma Services team including early phase and observational research. Sean is a recognized industry leader in Phase IV clinical trials, post-marketing surveillance programs, and patient registries. His experience spans all major therapeutic areas and all phases of research and development.
Dr. VanderWalde’s primary research is in melanoma, immunotherapy and targeted therapies based on immune markers and aberrations in cancer genetics. He is Vice President of Clinical Development, Caris Life Sciences, and Senior Medical Director, George Clinical. A thought leader in melanoma and clinical trial design and implementation, he has collaborated on advisory boards with many of the nation’s thought leaders and top experts in the field and previously served as United States Medical Lead and Clinical Research Medical Director with Amgen Inc., directing U.S. global development of talimogene laherparepvec, a novel viral-based immunotherapeutic that has shown efficacy in late-stage clinical trials in melanoma.
As Former Director of Research at West Cancer Center and Research Institute, Dr. VanderWalde was responsible for managing the portfolio of all clinical trials. He is the former Director of Precision Oncology at OneOncology.
2301 S King Dr
Meet with George Clinical! Contact us to schedule a time now.